Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Infect Chemother ; 27(1): 126-129, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33060046

ABSTRACT

Considering the issues of shortage of medical resources and the invasiveness and infection risk involved in the collection of nasopharyngeal swab specimens, there is a need for an effective alternative test specimen for SARS-CoV-2 RNA detection. Here, we investigated suitability of saliva as a non-invasively obtained specimen for molecular detection of SARS-CoV-2 RNA in Japanese patients with COVID-19. In total, 28 paired clinical specimens of saliva and nasopharyngeal swabs were collected from 12 patients at various time points after symptom onset. Each specimen was assayed using reverse transcription real-time polymerase chain reaction (rRT-PCR) on the BD MAX open system using primers and probes targeting the N-gene. The saliva and nasopharyngeal swab specimens showed 19 and 15 positive results, respectively. No invalid (PCR inhibition) result was observed for any specimen. The qualitative results of each specimen obtained in the period immediately after symptom onset were similar. Three convalescent patients presented saliva-positive results, whereas their nasopharyngeal swabs were negative at four different time points, suggesting that saliva may be superior to nasopharyngeal swabs in terms of obtaining stable assay result of SARS-CoV-2. In conclusion, our results suggest that saliva can potentially serve as an alternative to nasopharyngeal swabs as a specimen for SARS-CoV-2 rRT-PCR. As saliva can be collected by patients themselves, it may be an effective way to overcome the shortage of personal protective equipment and specimen sampling tools.


Subject(s)
Betacoronavirus/isolation & purification , Coronavirus Infections/diagnosis , Nasopharynx/virology , Pneumonia, Viral/diagnosis , RNA, Viral/isolation & purification , Saliva/virology , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques , Humans , Japan , Pandemics , Reverse Transcriptase Polymerase Chain Reaction , SARS-CoV-2 , Specimen Handling/methods
2.
J Infect Chemother ; 24(1): 31-35, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29066217

ABSTRACT

BACKGROUND: Central line-associated bloodstream infections (CLABSIs) are among the most serious complications especially in blood cancer patients. In January 2013, Centers for Disease and Prevention (CDC) introduced a new surveillance definition of mucosal barrier injury-associated laboratory-confirmed bloodstream infection (MBI-LCBI). This study was to determine the impact of MBI-LCBI on CLABSIs and compare the clinical characteristics of MBI versus non-MBI-LCBI cases. PATIENTS AND METHODS: We retrospectively reviewed the records of 250 consecutive patients. They were admitted in department of hematology at Aichi Medical University Hospital. We applied the revised 2013 CLABSI surveillance protocol to all CLABSI cases identified during the 47-months period from May 2012 through June 2016. RESULTS: A total of 44 CLABSIs were identified. The median patient age was 65 years (range, 12 to 89). Among 44 patients, 31 patients were diagnosed as leukemia (70.5%) and 12 patients as lymphoma (27.3%). Six patients underwent bone transplantation for leukemia or myelodysplastic syndrome (13.6%). A total of 20 patients (45.5%) were classified as MBI-LCBI and 24 (54.5%) were classified as non-MBI-LCBI. The primary disease type (P = 0.018), neutropenic within 3 days before CLABSI (MBI-LCBI vs. non-MBI-LCBI: 95.0% vs. 26.3%, P = <0.0001), line(s) removed owing to CLABSI (15.0% vs. 54.2%, P = 0.011) and Gram-negative organisms cultured (70.0% vs. 37.5%, P = 0.004) showed significantly difference between the groups. CONCLUSION: Our data showed that MBI-LCBI cases account for 45.5% of the CLABSI cases identified in blood cancer patients, and constituted a significant burden to this high-risk patient population.


Subject(s)
Bacteremia/etiology , Catheter-Related Infections/etiology , Central Venous Catheters/adverse effects , Leukemia/drug therapy , Lymphoma/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Bacteremia/epidemiology , Bacteria/isolation & purification , Catheter-Related Infections/epidemiology , Child , Female , Gastrointestinal Microbiome , Hospitals, University , Humans , Japan/epidemiology , Male , Middle Aged , Mucous Membrane/injuries , Mucous Membrane/microbiology , Retrospective Studies
3.
J Infect Chemother ; 23(10): 683-686, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28781099

ABSTRACT

BACKGROUND: We undertook a survey to evaluate the compliance and the tolerability of oseltamivir and zanamivir when they were used as post-exposure prophylaxis among the medical staffs in the 2014-2015 seasons to understand a characteristic of adverse events caused by anti-influenza (flu) agents. MATERIALS AND METHODS: During the study period, 540 medical staffs received oseltamivir (75 mg twice a day for 5 days) or zanamivir (twice a day for 5 days) as post-exposure prophylaxis of influenza, respectively. RESULTS: Four hundred eleven medical staffs of 540 medical staffs (76.1%) provided responses to questionnaire investigations. The adverse events caused by oseltamivir were reported by 86 of 382 medical staffs (22.5%). The most frequent adverse events were gastrointestinal adverse events (13.4%), followed by systemic and local diseases (11.8%), diseases of the nervous system (7.9%) and neuropsychiatric adverse events (0.5%). On the other hand, adverse events caused by zanamivir were reported by one (3.4%) of 29 medical staffs. CONCLUSION: Our survey revealed that 22.5% subjects experienced any adverse events due to oseltamivir. And the regimen showed low compliance than we expected. On the other hands, zanamivir showed high adherence with lower incidence of adverse events.


Subject(s)
Antiviral Agents/adverse effects , Drug-Related Side Effects and Adverse Reactions/etiology , Adult , Antiviral Agents/therapeutic use , Humans , Influenza, Human/drug therapy , Medical Staff , Middle Aged , Oseltamivir/adverse effects , Oseltamivir/therapeutic use , Post-Exposure Prophylaxis/methods , Retrospective Studies , Zanamivir/adverse effects , Zanamivir/therapeutic use
4.
Am J Infect Control ; 47(9): 1154-1156, 2019 09.
Article in English | MEDLINE | ID: mdl-31047689

ABSTRACT

In some Japanese hospitals, patients using infusion bags for parenteral nutrition containing amino acids have developed Bacillus cereus bloodstream infections. We considered that proliferation of contaminated B cereus in the bag during prolonged drip infusion might be one of the causes of infection. This study indicated that 8 h is the maximum appropriate drip infusion time for peripheral parental nutrition containing amino acids to prevent B cereus bloodstream infections.


Subject(s)
Amino Acids/adverse effects , Bacillus cereus/isolation & purification , Bacteremia/etiology , Drug Contamination , Gram-Positive Bacterial Infections/etiology , Infusions, Intravenous/adverse effects , Parenteral Nutrition/adverse effects , Amino Acids/administration & dosage , Bacteremia/microbiology , Cross Infection , Gram-Positive Bacterial Infections/microbiology , Humans , Infusions, Intravenous/methods , Japan , Parenteral Nutrition/methods
5.
Intern Med ; 57(4): 497-501, 2018.
Article in English | MEDLINE | ID: mdl-29445061

ABSTRACT

Objective From November 24 to December 9, 2013, an outbreak of the influenza (flu) A (H3) virus occurred in a tertiary-care university hospital (1,014 beds). We herein report the prophylactic effect of anti-flu agents for controlling the flu outbreak. Methods We administered pre- or post-exposure prophylaxis with anti-flu agents in flu outbreak. To test the effectiveness of prophylaxis in a flu outbreak, we used the posterior mean of the reproductive value during the pre- and post-intervention period. We also simulated the probability distribution of new flu cases. We performed an analysis to quantify the strength of the intervention effect. Results A total of 97 people were diagnosed with flu before the intervention, and 7 were diagnosed after the intervention. A molecular analysis of the flu virus revealed that this outbreak was due to the flu A (H3) virus. A total of 3,702 people received prophylaxis. There was a significant reduction in the reproductive value from 1.89 [95% confidence interval (CI), 1.59 to 2.24] to 0.65 (95% CI, 0.02 to 1.00) after the intervention (p<0.001). Conclusion Prophylaxis with anti-flu agents, along with prompt identification and isolation of infected individuals, was effective in reducing the impact of a flu outbreak in a hospital.


Subject(s)
Antiviral Agents/therapeutic use , Disease Outbreaks/prevention & control , Influenza, Human/drug therapy , Influenza, Human/prevention & control , Oseltamivir/therapeutic use , Female , Hospitals, University/statistics & numerical data , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL